Evolus Inc

EOLS remains in a confirmed Stage 4 decline with sequential lower highs and lower lows under downward‐sloping EMAs, reinforcing a bearish medium-term bias. Price is currently extended below the declining 9 EMA and 21 EMA into extreme oversold territory, indicating potential near-term exhaustion and unfavorable timing for further selling. We will defer execution and trim into any relief rally back toward the dynamic resistance zone around the 9/21 EMA or prior support-turned-resistance levels.

• ↑Q1 2026 net revenue reached $73.1M, up 7% YoY with $0.6M adjusted EBITDA
• ↑Analyst consensus ‘Moderate Buy’ with $16 target implies ~145% upside
• ↓Negative earnings yield and low book-to-price raise valuation concerns